Table of Contents
Strategic Performance Drivers
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
-
Delivered broad-based growth across all segments, driven by a deliberate enterprise-wide focus on margin recovery and operational discipline.
-
Aetna’s performance reflects the cumulative impact of coordinated actions over two years, resulting in over $2 billion of year-over-year improvement in adjusted operating income.
-
CVS Pharmacy has established itself as the ‘best-run national pharmacy’ through intentional investments in technology and colleague engagement, leading to consistent script growth and service excellence.
-
Strategic positioning in the GLP-1 market utilizes a multi-channel approach, capturing volume through funded benefits while expanding direct-to-consumer access via MinuteClinic and manufacturer partnerships.
-
The Health Services segment is navigating a transition toward greater transparency and net-cost pricing models, aiming to preserve PBM value while adapting to regulatory shifts.
-
Management is pivoting the company from a consumer-based healthcare provider to a consumer-based healthcare technology business, anchored by a $20 billion decade-long investment plan.
2027 Outlook and Strategic Assumptions
-
Established a preliminary 2027 adjusted EPS floor of $8.44, representing approximately 13% growth from the 2026 adjusted baseline.
-
Expects continued momentum in Aetna’s margin recovery over the next few years, supported by disciplined pricing and medical cost management in Medicare Advantage.
-
Anticipates 2027 headwinds in the Health Services segment due to ongoing 340B program dynamics and a more disciplined approach to PBM client renewals and underwriting.
-
Assumes a robust generic and biosimilar pipeline in 2027 will serve as a significant tailwind for the industry-leading specialty pharmacy business.
-
Guidance philosophy remains focused on credible targets and disciplined execution, with capital deployment currently limited to offsetting dilution until leverage improves.
Risk Factors and Structural Dynamics
-
The 340B program remains a dynamic risk as pharmaceutical manufacturers impose restrictions on covered entities, impacting purchasing economics.
-
Challenging unconstitutional pharmacy laws in states like Arkansas and Tennessee that management believes threaten care accessibility and affordability.
-
The transition to the CVS CostVantage model is intended to stabilize pharmacy reimbursement and align more closely with payer value, though it requires careful execution.
-
Aetna’s exit from the individual exchange business in 2026 resulted in a year-over-year membership decline of approximately 700,000 members.
